Recent advances in the development of novel mucosal adjuvants and antigen delivery systems

Chen, Wangxue; Patel, G. B.; Yan, Hong‐Bin; Zhang, Jianbing

doi:10.4161/hv.6.9.11561

Cited by 36 publications

(25 citation statements)

References 102 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Today, there is great interest in the development of novel mucosal adjuvants and antigen delivery systems [96,97]. However, those adjuvants whose mechanisms of action are based on the cytolytic effect cannot be used for this objective.…”

Section: Considerations Regarding Inoculation Routesmentioning

confidence: 99%

An approach to local immunotoxicity induced by adjuvanted vaccines

Batista-Duharte¹,

Portuondo

Carlos

et al. 2013

International Immunopharmacology

View full text Add to dashboard Cite

Section: Considerations Regarding Inoculation Routesmentioning

confidence: 99%

An approach to local immunotoxicity induced by adjuvanted vaccines

Batista-Duharte¹,

Portuondo

Carlos

et al. 2013

International Immunopharmacology

View full text Add to dashboard Cite

“…T he lack of a well-characterized, effective, and safe mucosal adjuvant is a serious problem in the development of efficacious mucosal vaccines (1)(2)(3). Most vaccine adjuvants are known to target innate signaling pathways that control the development of adaptive humoral and cellular immune responses, but the molecular mechanism of their action is still being characterized (4)(5)(6)(7)(8)(9)(10).…”

mentioning

confidence: 99%

Distinct Pathways of Humoral and Cellular Immunity Induced with the Mucosal Administration of a Nanoemulsion Adjuvant

Bielinska

Makidon

Janczak

et al. 2014

The Journal of Immunology

View full text Add to dashboard Cite

Nasal administration of an oil-in-water nanoemulsion (NE) adjuvant W805EC produces potent systemic and mucosal, Th-1– and Th-17–balanced cellular responses. However, its molecular mechanism of action has not been fully characterized and is of particular interest because NE does not contain specific ligands for innate immune receptors. In these studies, we demonstrate that W805EC NE adjuvant activates innate immunity, induces specific gene transcription, and modulates NF-κB activity via TLR2 and TLR4 by a mechanism that appears to be distinct from typical TLR agonists. Nasal immunization with NE-based vaccine showed that the TLR2, TLR4, and MyD88 pathways and IL-12 and IL-12Rβ1 expression are not required for an Ab response, but they are essential for the induction of balanced Th-1 polarization and Th-17 cellular immunity. NE adjuvant induces MHC class II, CD80, and CD86 costimulatory molecule expression and dendritic cell maturation. Further, upon immunization with NE, adjuvant mice deficient in the CD86 receptor had normal Ab responses but significantly reduced Th-1 cellular responses, whereas animals deficient in both CD80 and CD86 or lacking CD40 failed to produce either humoral or cellular immunity. Overall, our data show that intranasal administration of Ag with NE induces TLR2 and TLR4 activation along with a MyD88-independent Ab response and a MyD88-dependent Th-1 and Th-17 cell–mediated immune response. These findings suggest that the unique properties of NE adjuvant may offer novel opportunities for understanding previously unrecognized mechanisms of immune activation important for generating effective mucosal and systemic immune responses.

show abstract

“…[26][27][28] Previous studies have shown that chitosan (CS) and TMC NPs are efficient vaccine delivery systems for systemic vaccination. [29][30][31][32] In another study, Slutter et al compared CS and TMC NPs' function in oral immunization.…”

Section: Discussionmentioning

confidence: 99%

Oral immunization of mice with Omp31-loaded <em>N</em>-trimethyl chitosan nanoparticles induces high protection against <em>Brucella melitensis</em> infection

Abkar¹,

Fasihi-Ramandi²,

Kooshki³

et al. 2017

IJN

View full text Add to dashboard Cite

Brucellosis is a group of closely associated zoonotic bacterial illnesses caused by members of the genus Brucella. B. melitensis Omp31 is a promising candidate for a subunit vaccine against brucellosis. This study surveyed the immunogenicity of Omp31 alone and with incomplete Freund’s adjuvant (Omp31-IFA) and N -trimethyl chitosan (TMC/Omp31) nanoparticles (NPs), as well as the effect of Omp31 immunization route on immunological responses and protection. After expression and purification, the recombinant Omp31 (rOmp31) was loaded onto TMC NPs by ionic gelation. The particle size, loading efficiency and in vitro release of the NPs were examined. Omp31-IFA was administered intraperitoneally, while TMC/Omp31 NPs were administered orally and intraperitoneally. According to the antibody subclasses and cytokine profile, intraperitoneal immunization by Omp31-IFA and TMC/Omp31 NPs induced T helper 1 (Th1) and Th1–Th2 immune responses, respectively. On the other hand, oral immunization with TMC/Omp31 NPs elicited a mixed Th1–Th17 immune response. Data obtained from the cell proliferation assay showed that vaccination with Omp31 stimulated a vigorous antigen-specific cell proliferative response, which could be further increased after oral immunization with TMC/Omp31 NPs. Vaccinated groups of mice when challenged with B. melitensis 16M were found to be significantly protected in the orally administered group in comparison with the intraperitoneally immunized mice. Results of this study indicated that the reason for high protection after oral vaccination can be via elicited Th17 response.

show abstract

Recent advances in the development of novel mucosal adjuvants and antigen delivery systems

Cited by 36 publications

References 102 publications

An approach to local immunotoxicity induced by adjuvanted vaccines

An approach to local immunotoxicity induced by adjuvanted vaccines

Distinct Pathways of Humoral and Cellular Immunity Induced with the Mucosal Administration of a Nanoemulsion Adjuvant

Oral immunization of mice with Omp31-loaded <em>N</em>-trimethyl chitosan nanoparticles induces high protection against <em>Brucella melitensis</em> infection

Contact Info

Product

Resources

About